Q3 2020 Sales Performance slide image

Q3 2020 Sales Performance

• Dostarlimab (PD-1 antagonist) • Endometrial cancer is the most common gynecological cancer in the US GARNET is the largest study of anti-PD-1 monotherapy in patients with recurrent or advanced endometrial cancer Data at SGO 2020 in patients with recurrent or advanced dMMR endometrial cancer Overall response rate (ORR) of 42% and disease control rate (DCR) 58%, by RECIST v1.1* Development strategy for use in: 2/3L treatment in patients with advanced solid tumors (GARNET) 1L Treatment (RUBY) Study start Read-out monotherapy dMMR/MSI-H EC pivotal 2017 2H19 BLA accepted, n=75 Presented at SGO 2020 dMMR/MSI-H tumor agnostic monotherapy pivotal 2018 2H20 n=50 MMRP/MSS EC pivotal monotherapy n=100 2017 2H19 Endometrial cancer pivotal dMMR/MSI-H and MMRP/MSS patients combo w chemo n=470 2H 2019 2021 As determined by NGS test ** Based on pooled data from studies that used either 200 mg every 3 weeks or 10 mg/kg every 2 weeks gsk 55 59
View entire presentation